26-A-12106-ACC LIPOPROTEIN(A)-TARGETED THERAPIES VERSUS PLACEBO/STANDARD CARE IN ASCVD: EFFECTS ON MACE, LP(A) REDUCTION AND SAFETY — SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS
JACC · 2026-04 · 87 (13) · A186-A187
DOI: 10.1016/j.jacc.2026.02.464 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JACC, 2026-04. Verfasst von Oluwasolabomi Onadipe und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Onadipe, O., Yuce, S., Lanka, N., Onadipe, K., & Nalam, R. (2026). 26-A-12106-ACC LIPOPROTEIN(A)-TARGETED THERAPIES VERSUS PLACEBO/STANDARD CARE IN ASCVD: EFFECTS ON MACE, LP(A) REDUCTION AND SAFETY — SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. JACC, 87(13), A186-A187. https://doi.org/10.1016/j.jacc.2026.02.464
Vancouver
Onadipe O, Yuce S, Lanka N, Onadipe K, Nalam R. 26-A-12106-ACC LIPOPROTEIN(A)-TARGETED THERAPIES VERSUS PLACEBO/STANDARD CARE IN ASCVD: EFFECTS ON MACE, LP(A) REDUCTION AND SAFETY — SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. JACC. 2026;87(13):A186-A187. doi:10.1016/j.jacc.2026.02.464
BibTeX
@article{Onadipe2026,
author = {Onadipe, Oluwasolabomi and Yuce, Servet and Lanka, Nidhi and Onadipe, Kanyinsola and Nalam, Ridhinayani},
title = {26-A-12106-ACC LIPOPROTEIN(A)-TARGETED THERAPIES VERSUS PLACEBO/STANDARD CARE IN ASCVD: EFFECTS ON MACE, LP(A) REDUCTION AND SAFETY — SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A186--A187},
doi = {10.1016/j.jacc.2026.02.464}
}
EUVIMED